NCT02478255View on ClinicalTrials.gov

Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

January 13, 2022

Study Completion Date

January 13, 2022

Conditions
Radiation Injury
Interventions
DRUG

Hyperpolarized 129-Xenon gas

Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.

DEVICE

MRI

Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.

Trial Locations (1)

27713

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Bastiaan Driehuys

OTHER

NCT02478255 - Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment | Biotech Hunter | Biotech Hunter